Archives
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Fibronectin protein level was not affected by DIF although f
2021-12-28

Fibronectin protein level was not affected by DIF-1, although fibronectin has also been considered a canonical Wnt signaling pathway target gene product [39]. Thus, the canonical Wnt signaling pathway may not be critical for the regulation of the expression of fibronectin in malignant melanoma cells
-
Telbivudine australia br Materials and methods br Results
2021-12-28

Materials and methods Results Discussion Conclusion Pharmacophore modeling was applied to explore new probable Glo-I inhibitors. Ninety two pharmacophoric models were generated representing diverse types of interaction between co-crystallized ligands and corresponding binding site. The g
-
br Conclusions br Acknowledgements br
2021-12-28

Conclusions Acknowledgements Introduction Glucose metabolism is vital to prepare uterine epithelium and stroma for embryo implantation and for the differentiation of the functionalis layer to support the developing conceptus [[1], [2], [3], [4]]. Due to its polar nature and hydrophilic cond
-
The experiments indicate that a major component of the vasod
2021-12-27

The experiments indicate that a major component of the vasodilatation is due to antagonism of α 1-adrenoceptors. Evidence for α1-adrenoceptor antagonism is that vasodilatation was observed in Ac-YVAD-CHO preconstricted with α1-adrenoceptor agonists, phenylephrine or methoxamine, but not in vessels
-
After initial optimization of the distances we obtained the
2021-12-27

After initial optimization of the distances we obtained the structure iG shown schematically in Fig. 1. This is the telomeric fragment of chromosome with the noncanonical structures of i-motif and G-quadruplex placed symmetrically in the middle of the duplex. Obviously, we consider the situation whe
-
Sirolimus rapamycin and everolimus both of which
2021-12-27

Sirolimus (rapamycin) and everolimus, both of which are mTOR inhibitors, are released by commonly used first- and second-generation DES. Considering the relatively high rates of the target vessel failure with currently available DES [12,14,16,45,46], there is a need for a novel drug strategy that pr
-
Overall we partially confirmed our predictions and
2021-12-27

Overall, we partially confirmed our predictions, and, when compared to the other existing dataset exploring the interaction among CRFR1, FAAH, and anxiety, our data are somewhat confirmatory. Demers and colleagues (Demers et al., 2016) found one (protective) CRFR1 minor allele (rs110402) and the (le
-
The even bigger surprise was the second
2021-12-27

The even bigger surprise was the second feature of both structures. Interestingly, binding of the MRG domain hardly altered the conformation of the SET domain compared with its apo state (An et al., 2011). What did change, however, is the conformation of the ASH1L auto-inhibitory loop (Figure 1). De
-
Furthermore Rosethorne and Charlton Panula et al Reher et al
2021-12-27

Furthermore, Rosethorne and Charlton (Panula et al., 2015, Reher et al., 2012, Rosethorne and Charlton, 2011) expressed the human H4R in an osteosarcoma cell line and found that with respect to [35S]GTPγS binding, JNJ-7777120 acted as a neutral antagonist or very weak inverse agonist, a finding whic
-
Fig summarizes the results for M concentration of the drugs
2021-12-27

Fig. 1 summarizes the results for 500 μM concentration of the drugs. Action of histamine is presented for comparison. Both 1-methylhistamine and Nα-methylhistamine strongly potentiated ASIC1a responses. The concentration-dependence of action of Nα-methylhistamine was measured (Fig. 1B). Fitting by H
-
Importantly HDACi mediated effects are cell and HDAC specifi
2021-12-27

Importantly, HDACi-mediated effects are cell and HDAC specific; different effects and outcomes have been observed in different cell types, targeting different HDAC isoforms. While HDACi exhibit a strong proapoptotic potential in human leukemia custom synthesis 19, 20, 21, 22, they have a limited ab
-
Accessibility and physico chemical features of cysteine resi
2021-12-27

Accessibility and physico-chemical features of cysteine residues define their redox-reactivity and the 3-dimensional structure of GSNOR allows to identifying such surface-exposed, redox-sensitive cysteine residues. GSNOR crystal structures are available from human (Protein Data Bank code: 1MP0), tom
-
Several studies have found that GPR possesses a distinct
2021-12-27

Several studies have found that GPR55 possesses a distinct pharmacology from that of CB1 and CB2, and that only certain cannabinoids act at this receptor. In transfected FTY720 Phosphate expressing hGPR55, out of more than 20 synthetic and endogenous cannabinoids evaluated, only 2 compounds, SR1417
-
As well as the above studies Meier and coworkers used
2021-12-27

As well as the above studies, Meier and coworkers used TUG-891, alongside omega-3 fatty acids, to show a potential role for FFA4 in inhibiting proliferation of DU145 prostate cancer cells [68]. Given that these cells express both FFA4 and FFA1 and the current view that TUG-891 may not be sufficientl
-
br Acknowledgements We thank the support
2021-12-27

Acknowledgements We thank the support of the National Natural Science Foundation of China (NSFC) project 81501342 and support from the Disciplinary Group of Oncology and Immunology program of Xinxiang Medical University. Introduction First described as a new clinical entity in 1981, the Acqui
16189 records 525/1080 page Previous Next First page 上5页 521522523524525 下5页 Last page